<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394015</url>
  </required_header>
  <id_info>
    <org_study_id>GEICO 1402R</org_study_id>
    <secondary_id>GEI-TRAB-2014-01</secondary_id>
    <nct_id>NCT02394015</nct_id>
  </id_info>
  <brief_title>Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC</brief_title>
  <acronym>RETRO-ROC</acronym>
  <official_title>Multicenter and Retrospective Observational Study to Analyze the Efficacy and Safety of the Combination With Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to Data Sheet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Investigación en Cáncer de Ovario</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español de Investigación en Cáncer de Ovario</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal
      Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian
      Cancer (ROC), According to SmPC.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy progression-free survival (PFS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Describe the impact of trabectedin - pegylated liposomal doxorubicin combination of retreatment with platinum ROC, in terms of progression-free survival ( PFS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Describe the impact of trabectedin - pegylated liposomal doxorubicin combination of retreatment with platinum ROC, in terms of overall survival (OS ) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate to previous and post-treatment (Percentage of responses (CR+PR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of responses (CR+PR) at pretreatment and post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate to trabectedin - DLP combination (Percentage of responses (CR+PR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of responses ( CR + PR ) to trabectedin - DLP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit in 4 months (Percentage of clinical benefit (CR + PR + SD)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of clinical benefit (CR + PR + SD for at least 4 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of trabectedin - PLD combination in subsequent treatments</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessment of the impact of treatment with trabectedin - PLD combination at the beginning of subsequent treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (adverse events)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>type , incidence , severity, frequency, severity and relationship to the treatment of adverse events reported in patients reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between PFS and PFS2</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Comparison of the PFS of prior platinum combination TRB + DLP and subsequent platinum PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypersensitivity and allergic reactions (Number and Management of hypersensitivity reactions or allergies)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Number and Management of hypersensitivity reactions or allergies.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ovarian Epithelial Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Trabectedin+ PLD</arm_group_label>
    <description>Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin and Pegylated Liposomal Doxorubicin</intervention_name>
    <description>Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014</description>
    <arm_group_label>Trabectedin+ PLD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have received treatment with trabectedin - DLP for recurrent ovarian cancer
        according to SMPC, between October 28, 2009 and October 31, 2014 and which have not been
        included in clinical trials where the IMP was trabectedin.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have received at least one dose of trabectedin - doxorubicin pegylated
             for recurrent ovarian cancer according to SMPC, between October 28, 2009 and October
             31, 2014 and which have not been included in clinical trials where the IMP was
             trabectedin.

        Exclusion Criteria:

          -  Patients with records unavailable (lost, empty or not recoverable).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Vidal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Clinic, Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose M Del Campo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Vall d'Hebron, Barcelona</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>August 10, 2016</last_update_submitted>
  <last_update_submitted_qc>August 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platinum-sensitive Recurrent Ovarian Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

